Enliven Therapeutics Inc (ELVN) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ELVN Annual Balance Sheets →
From Enliven Therapeutics Inc through Jun 30 2025, shifts in Jun 30 2026's assets and liabilities provide insight into the company's capital structure and financial stability.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent895.20
Marketable Securities, Current SH759.65
Cash & Short-term Investments1,654.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current12.18
Total Current Assets907.34
Equipment/Property/Plant Net0.39
Other Assets, Noncurrent2.49
Operating Lease Right Of Use Asset0.29
Total Assets910.22
Liabilities
Accounts Payable, Current AC0.37
Accrued Liabilities, Current4.44
Other Liabilities, Current9.35
Total Current Liabilities14.16
Total Long-term Debt0.00
Other liabilities, Noncurrent0.91
Accrued Expenses And Other Current Liabilities9.85
Total Liabilities15.07
Stockholders' Equity
Common Stock Value0.07
Additional Paid In Capital Common Stock1,300.26
Retained Earnings / Accumulated Deficit-403.28
Accumulated Other Comprehensive Income-1.91
Other Equity-1.91
Common Stockholder's Equity895.15
Total Stockholder's Equity895.15
Liabilities & Stockholder's Equity910.22
4 historic quarters locked

Sign in to unlock the full Enliven Therapeutics Inc balance sheet history.

About Enliven Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-335155

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.